Geoffrey Rezvani1, Julian C K Lui, Kevin M Barnes, Jeffrey Baron. 1. Program on Developmental Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland, USA. grezvani@drexelmed.edu
Abstract
INTRODUCTION: In many normal tissues, proliferation rates decline postnatally, causing somatic growth to slow. Previous evidence suggests that this decline is due, in part, to decline in the expression of growth-promoting imprinted genes including Mest, Plagl1, Peg3, Dlk1, and Igf2. Embryonal cancers are composed of cells that maintain embryonic characteristics and proliferate rapidly in childhood. We hypothesized that the abnormal persistent rapid proliferation in embryonal cancers occurs in part because of abnormal persistent high expression of growth-promoting imprinted genes. RESULTS: Analysis of microarray data showed elevated expression of MEST, PLAGL1, PEG3, DLK1, and IGF2 in various embryonal cancers, especially rhabdomyosarcoma, as compared to nonembryonal cancers and normal tissues. Similarly, mRNA expression, assessed by real-time PCR, of MEST, PEG3, and IGF2 in rhabdomyosarcoma cell lines was increased as compared to nonembryonal cancer cell lines. Furthermore, siRNA-mediated knockdown of MEST, PLAGL1, PEG3, and IGF2 expression inhibited proliferation in Rh30 rhabdomyosarcoma cells. DISCUSSION: These findings suggest that the normal postnatal downregulation of growth-promoting imprinted genes fails to occur in some embryonal cancers, particularly rhabdomyosarcoma, and contributes to the persistent rapid proliferation of rhabdomyosarcoma cells and, more generally, that failure of the mechanisms responsible for normal somatic growth deceleration can promote tumorigenesis.
INTRODUCTION: In many normal tissues, proliferation rates decline postnatally, causing somatic growth to slow. Previous evidence suggests that this decline is due, in part, to decline in the expression of growth-promoting imprinted genes including Mest, Plagl1, Peg3, Dlk1, and Igf2. Embryonal cancers are composed of cells that maintain embryonic characteristics and proliferate rapidly in childhood. We hypothesized that the abnormal persistent rapid proliferation in embryonal cancers occurs in part because of abnormal persistent high expression of growth-promoting imprinted genes. RESULTS: Analysis of microarray data showed elevated expression of MEST, PLAGL1, PEG3, DLK1, and IGF2 in various embryonal cancers, especially rhabdomyosarcoma, as compared to nonembryonal cancers and normal tissues. Similarly, mRNA expression, assessed by real-time PCR, of MEST, PEG3, and IGF2 in rhabdomyosarcoma cell lines was increased as compared to nonembryonal cancer cell lines. Furthermore, siRNA-mediated knockdown of MEST, PLAGL1, PEG3, and IGF2 expression inhibited proliferation in Rh30rhabdomyosarcoma cells. DISCUSSION: These findings suggest that the normal postnatal downregulation of growth-promoting imprinted genes fails to occur in some embryonal cancers, particularly rhabdomyosarcoma, and contributes to the persistent rapid proliferation of rhabdomyosarcoma cells and, more generally, that failure of the mechanisms responsible for normal somatic growth deceleration can promote tumorigenesis.
Authors: Craig C Whiteford; Sven Bilke; Braden T Greer; Qingrong Chen; Till A Braunschweig; Nicola Cenacchi; Jun S Wei; Malcolm A Smith; Peter Houghton; Christopher Morton; C Patrick Reynolds; Richard Lock; Richard Gorlick; Chand Khanna; Carol J Thiele; Mikiko Takikita; Daniel Catchpoole; Stephen M Hewitt; Javed Khan Journal: Cancer Res Date: 2007-01-01 Impact factor: 12.701
Authors: Elizabeth M Algar; Luke St Heaps; Artur Darmanian; Vinod Dagar; Dirk Prawitt; Greg B Peters; Felicity Collins Journal: Cancer Res Date: 2007-02-26 Impact factor: 12.701
Authors: Malcolm A Smith; Christopher L Morton; Doris Phelps; Kevin Girtman; Geoffrey Neale; Peter J Houghton Journal: Pediatr Blood Cancer Date: 2008-03 Impact factor: 3.167
Authors: Mark E Hatley; Wei Tang; Matthew R Garcia; David Finkelstein; Douglas P Millay; Ning Liu; Jonathan Graff; Rene L Galindo; Eric N Olson Journal: Cancer Cell Date: 2012-10-16 Impact factor: 31.743
Authors: Louise H Jørgensen; Jeeva Sellathurai; Erica E Davis; Tania Thedchanamoorthy; Rua W A Al-Bader; Charlotte H Jensen; Henrik D Schrøder Journal: PLoS One Date: 2013-04-05 Impact factor: 3.240
Authors: Adam Stevens; Daniel Hanson; Andrew Whatmore; Benoit Destenaves; Pierre Chatelain; Peter Clayton Journal: BMC Genomics Date: 2013-08-13 Impact factor: 3.969